Drugs & Targets EC approves Padcev + Keytruda as perioperative treatment option for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer June 26, 2026Vol.52 No.25
Drugs & Targets FDA approves Ambelvist for contrast-enhanced MRI to detect and visualize lesions with abnormal vascularity June 18, 2026Vol.52 No.24
Drugs & Targets FDA accepts sBLA for atezolizumab for patients with stage 3 dMMR colon cancer June 18, 2026Vol.52 No.24
Drugs & Targets FDA warns providers about shortage of breast biopsy needles June 18, 2026Vol.52 No.24
Drugs & Targets FDA expands sunscreen options for the first time in 20 years June 12, 2026Vol.52 No.23
Drugs & Targets FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer June 05, 2026Vol.52 No.22
Drugs & Targets FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm June 05, 2026Vol.52 No.22
